دورية أكاديمية
A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy.
العنوان: | A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy. |
---|---|
المؤلفون: | Lee CT; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: charles.lee@fccc.edu., Koleoso O; Doctor of Osteopathic Medicine Program, Philadelphia College of Osteopathic Medicine, Philadelphia, PA., Deng M; Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA., Veltchev I; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA., Lin T; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA., Hallman MA; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA., Horwitz EM; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA., Wong JK; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. |
المصدر: | Brachytherapy [Brachytherapy] 2023 Sep-Oct; Vol. 22 (5), pp. 586-592. Date of Electronic Publication: 2023 Jun 30. |
نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier, 2002- Country of Publication: United States NLM ID: 101137600 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-1449 (Electronic) Linking ISSN: 15384721 NLM ISO Abbreviation: Brachytherapy Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: New York, NY : Elsevier, 2002- |
مواضيع طبية MeSH: | Brachytherapy*/methods , Prostatic Neoplasms*/radiotherapy, Male ; Humans ; Hydrogels ; Radiotherapy Dosage ; Radiometry ; Rectum |
مستخلص: | Purpose: We hypothesize rectal hydrogel spacer (RHS) improves rectal dosimetry in patients undergoing salvage high-dose-rate brachytherapy (HDR-BT) for intact, recurrent prostate cancer (PC). Methods and Materials: A prospectively collected institutional database was queried for recurrent PC patients treated with salvage HDR-BT from September 2015 to November 2021. Patients were offered RHS beginning June 2019. Dosimetric variables were compared between RHS and no-RHS groups for the average of two fractions using Wilcoxon rank-sum tests. Primary outcomes were rectal volume receiving 75% of prescription dose (V75%) and prostate volume receiving 100% of prescription dose (V100%). Generalized estimating equation (GEE) model was used to evaluate the association between other planning variables and rectal V75%. Results: Forty-one PC patients received salvage HDR-BT, of whom 20 had RHS. All patients received 2400cGy in 2 fractions. Median RHS volume was 6.2cm 3 (Standard deviation [SD]: ± 3.5cm 3 ). Median follow-up was 4 months and 17 months in the RHS and no-RHS groups, respectively. Median rectal V75% with and without RHS were 0.0cm3 (IQR: 0.0-0.0cm3) and 0.06cm3 (IQR: 0.0-0.14cm3), respectively (p<0.001). Median prostate V100% with and without RHS were 98.55% (IQR: 97.86-99.22%) and 97.78% (IQR: 97.50-98.18%), respectively (p = 0.007). RHS, rectum, and prostate volumes did not significantly affect rectal V75% per GEE modeling. There was 10% G1-2 and 5% G3 rectal toxicity in RHS group. There was 9.5% G1-2 and no G3+ rectal toxicities in the no-RHS group. Conclusions: Absolute improvement in rectal V75% and prostate V100% was significant with RHS in PC patients undergoing salvage HDR-BT, but clinical benefit is marginal. (Copyright © 2023 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.) |
References: | J Med Imaging Radiat Oncol. 2021 Jun;65(3):384-397. (PMID: 33855816) Brachytherapy. 2018 Mar - Apr;17(2):251-258. (PMID: 29241706) Cancer. 2010 Nov 15;116(22):5226-34. (PMID: 20690197) Jpn J Clin Oncol. 2007 Feb;37(2):121-6. (PMID: 17255159) Front Oncol. 2021 Sep 09;11:681448. (PMID: 34568012) J Med Imaging Radiat Oncol. 2019 Dec;63(6):836-841. (PMID: 31520465) Pract Radiat Oncol. 2021 Nov-Dec;11(6):515-526. (PMID: 34077809) J Contemp Brachytherapy. 2017 Apr;9(2):146-150. (PMID: 28533803) Radiother Oncol. 2019 Dec;141:144-148. (PMID: 31564554) Brachytherapy. 2016 May-Jun;15(3):283-287. (PMID: 26853354) Eur Urol. 2021 Sep;80(3):280-292. (PMID: 33309278) Radiother Oncol. 2019 Dec;141:156-163. (PMID: 31570236) Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):971-977. (PMID: 26054865) Int Urol Nephrol. 2019 Jul;51(7):1101-1106. (PMID: 30977019) JAMA. 2012 Apr 18;307(15):1611-20. (PMID: 22511689) Pract Radiat Oncol. 2022 Nov-Dec;12(6):e531-e537. (PMID: 35718075) Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):817-24. (PMID: 16297567) Front Oncol. 2022 Aug 26;12:971344. (PMID: 36091157) Clin Transl Radiat Oncol. 2020 Dec 11;27:1-7. (PMID: 33364450) Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):324-9. (PMID: 23474112) J Contemp Brachytherapy. 2019 Feb;11(1):8-13. (PMID: 30911304) Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1106-12. (PMID: 17197119) Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):842-7. (PMID: 23845840) Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):318-322. (PMID: 27475672) Brachytherapy. 2017 Jan - Feb;16(1):186-192. (PMID: 28341011) Brachytherapy. 2010 Oct-Dec;9(4):328-34. (PMID: 20116341) |
معلومات مُعتمدة: | P30 CA006927 United States CA NCI NIH HHS |
فهرسة مساهمة: | Keywords: Dosimetry; High dose-rate brachytherapy; Prostate cancer; Rectal hydrogel spacer; Reirradiation; Salvage therapy |
المشرفين على المادة: | 0 (Hydrogels) |
تواريخ الأحداث: | Date Created: 20230701 Date Completed: 20231102 Latest Revision: 20231103 |
رمز التحديث: | 20231104 |
مُعرف محوري في PubMed: | PMC10527788 |
DOI: | 10.1016/j.brachy.2023.06.003 |
PMID: | 37393186 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1873-1449 |
---|---|
DOI: | 10.1016/j.brachy.2023.06.003 |